Screener
Scholar Rock SRRK Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Scholar Rock in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Scholar Rock’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:20 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336732
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | (4,518) | (1,206) | (6,820) | (3,025) |
| Other expense, net | (570) | (127) | (1,360) | (171) |
| Total other income (expense), net | (995) | 2,078 | (4,489) | 4,445 |
| Net loss | $$(109,896) | (110,031) | $(215,406) | $(184,754) |
| Net loss per share, basic and diluted | $$(0.84) | (0.98) | $(1.67) | $(1.65) |
| Weighted average common shares outstanding, basic and diluted | 130,612,734 | 112,703,014 | 128,954,153 | 112,273,032 |
| Comprehensive loss: | ||||
| Net loss | $$(109,896) | (110,031) | $(215,406) | $(184,754) |
Item 1. Financial Statements
FAQ
- What is Scholar Rock's business segments — net income loss?
- Scholar Rock (SRRK) reported business segments — net income loss of -$109.9M in Q2 2026.
- How has Scholar Rock's business segments — net income loss changed year-over-year?
- Scholar Rock's business segments — net income loss increased by 0.1% year-over-year, from -$110.03M to -$109.9M.
- What is the long-term trend for Scholar Rock's business segments — net income loss?
- Over 2 years (2023 to 2025), Scholar Rock's business segments — net income loss has grown at a 51.0% compound annual growth rate (CAGR), from -$165.79M to -$377.94M.
- What does business segments — net income loss mean?
- This represents the bottom-line financial result for the business segment after accounting for all revenues, operating expenses, and non-operating items. It is the primary indicator of the segment's overall financial health and sustainability. For early-stage biopharmaceutical companies, this metric typically highlights the ongoing cash burn required to fund clinical development.
Ask your AI about Scholar Rock's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude